IIgANN®2025：耐赋康®最新真实世界研究证实长期对因治疗持续展现良好有效性与安全性

Core Insights - A significant observational study confirms that NEFECON (budenoside enteric-coated capsules) provides substantial clinical benefits in the "etiological treatment" of IgA nephropathy, supporting a new management strategy focused on early and long-term treatment [1][4] Group 1: Study Findings - After 12 months of treatment, the NEFECON group showed a reduction in 24-hour urinary protein from 1016 mg to 114 mg, significantly lower than the control group's 291 mg [3] - The estimated glomerular filtration rate (eGFR) slope in the NEFECON group was significantly better than the control group, at 5.4 ml/min/1.73m²/year compared to -3.4 ml/min/1.73m²/year [3] - No severe infections occurred in the NEFECON group, indicating a better safety profile compared to traditional treatments [3] Group 2: Clinical Implications - The 2025 version of the "Clinical Practice Guidelines for Adult IgA Nephropathy" emphasizes the importance of long-term treatment strategies, including immunotherapy, to maintain kidney function and reduce the risk of renal failure [4] - NEFECON is the only approved drug for the etiological treatment of IgA nephropathy, recommended by both domestic and international guidelines for its ability to intervene at the disease's source [4][5] - The latest real-world study results presented at IIgANN 2025 reinforce NEFECON's position as a cornerstone treatment for IgA nephropathy, demonstrating sustained patient benefits after extending treatment beyond the initial 9 months [4][5] Group 3: Market Context - There are over 5 million IgA nephropathy patients in China, with more than 100,000 new cases diagnosed annually, highlighting a significant unmet clinical need [5] - NEFECON is the first and only drug for IgA nephropathy to receive full approval in China, the US, and Europe, not limited by urinary protein levels, thus reshaping treatment pathways for this condition [5]